COVID-19: Sunitinib (Sutent)
Sunitinib (Sutent) can be used to treat some people with malignant gastrointestinal stromal tumour (GIST).
Page updated: 30 March 2020
Renewal of Special Authority
We have amended the renewal criteria for sunitinib (Sutent) so that radiologic assessment is not necessary for ongoing funding. This change will be implemented by adding a new renewal category as below. It comes into effect on 1 April 2020.
New renewal category in Section B of the Pharmaceutical Schedule
Renewal - (GIST pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:
- The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- Sunitinib is to be discontinued at progression; and
- The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.
Section H of the Pharmaceutical Schedule will also be amended to reflect this change.
Changes are temporary
We intend change the criteria back to the current status once health services have stabilised to a point where it becomes practical to reinstate them.
Who to contact
If you have any questions about this change, email email@example.com
Last updated: 15 April 2020